Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
841 Leser
Artikel bewerten:
(2)

Xybion Digital Inc: Envol Biomedical selects Xybion's Preclinical Gold Standard LIMS, Pristima, to Digitize Lab Operations

Xybion's Preclinical LIMS Unifies and Enhances Laboratory Efficiency and Data Integrity for EnvolBio's CRO operations.

PRINCETON, NJ / ACCESSWIRE / April 15, 2024 / Xybion Digital announced today its partnership with EnvolBio to digitize lab operations for end-to-end non-clinical process standardization, streamline data for faster lab operation, manage quality, improve data integrity and compliance. This end-to-end preclinical gold standard solution helps the R&D teams with the ability to seamlessly perform study planning, cost management, protocol creation, study execution, data management, reporting, and regulatory submissions of non-clinical research and development studies.

As a world-leading, research-driven CRO, EnvolBio creates value through specialized primate studies and preclinical and clinical pharmacology services for drug discovery, toxicology, and clinical trials. "The nonclinical lab processes and data management are a critical part of EnvolBio's development, and the enhanced processes will make studies a lot more efficient. EnvolBio is excited to partner with Xybion and its end-to-end, fully unified solution, which will support us to run nearly the entire process from a single system. This improves the business user experience significantly, offers more flexibility, and simplifies the IT ecosystem through a single platform instead of operating multiple systems," says Jacob McDonald, CEO of EnvolBio, responsible for this program.

The Pristima LIMS SaaS software offers a complete digital lab environment:

  • Protocol Management
  • Planning, Cost and Resource Management
  • Toxicology
  • Pathology and Digital Pathology
  • Histology
  • Veterinary Management, IACUC
  • Colony Management
  • Pharmacy
  • Master Schedule, audits, non-conformance, CAPA
  • CDSIC SEND
  • Historical Controls Database (HCDB), Reporting and Analytics.
  • Lab Datalake and Artificial Intelligence

Mr. Kamal Biswas, President and COO of Xybion, says, "We are super excited to start this partnership. Xybion's LIMS creates an end-to-end digital laboratory execution environment not only for internal EnvolBio existing labs, but it also creates a future expansion path to streamline workflows, automation, data management, and artificial intelligence solutions. I'm very happy to support Jacob and his team to achieve their lab digitization goals."

"We are exceptionally proud to have been selected by EnvolBio as their partner for the digital acceleration of lab operations. This win bolsters Xybion Digital's track record as a trusted partner to large multinationals operating in the life sciences industry," said Dr. Pradip Banerjee, Chairman and CEO of Xybion Digital.

About Xybion Digital Inc.

Xybion is a leading software solution and consulting company dedicated to helping corporations solve business problems and create new capabilities. Through intelligently designed systems and business processes, we help companies become more efficient, reduce costs, and manage compliance, regulatory adherence, and risk. Serving more than 350 customers in 35 countries, we have the global scale and expertise to bring employees around the world to help companies in life sciences, healthcare, manufacturing, workplace health, and government. We put our expertise into action every day to help companies transform the digital workplace. Our unique solutions focus on integrated preclinical lab management, early-stage drug discovery, digital lab solutions, regulatory compliance, GRC, quality management, predictive compliance, content management, and systems validation. Since its founding in 1977, Xybion has supported most of the top 20 global life sciences companies through software, services, and consulting.

About Envol BioMedical

Envol Biomedical offers preclinical pharmacology and toxicology services for drug discovery and development in support of small molecules, gene therapy, and biologics. Envol Biomedical has access to the largest population of readily available naïve and non-naïve non-human primates (old-world and new world) in the continental U.S. Envol Biomedical provides cost-effective quality pharmacokinetic and pharmacodynamic studies with extremely fast turn-around time. Envol Biomedical is dedicated to the on-time delivery of study samples and study reports (standard and specific study protocols).

Contacts:

Media
Joseph Kalina
Xybion Digital
609-512-5790 x 316
jkalina@Xybion.com

SOURCE: Xybion Digital Inc.



View the original press release on accesswire.com

© 2024 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.